Hengrui Pharma Licenses GLP-1/GIP Dual Agonist HRS-1596 to Novo Nordisk in Deal Worth Up to $2.6B

The significance is less about the headline number than about the structure: a Chinese developer is handing a once-weekly oral dual agonist to Novo Nordisk, the incumbent in incretin therapies, rather than trying to commercialize it alone. That suggests the value now sits in clinical execution and global reach, not in early-stage molecule discovery. The open question is whether this becomes a template for other Chinese metabolic assets, or a one-off, and how much of the potential total is actually tied to milestones.